header logo image


Page 492«..1020..491492493494..500510..»

ONE Championship lays off sizable chunk of workforce to ensure its longevity – Bloody Elbow

June 18th, 2020 8:50 am

ONE Championship announced on Monday that theyre laying off 20% of their workforce.

The Singapore-based MMA promotion, which has been known for making very bold claims, unsurprisingly had their unique way of revealing the unfortunate news.

Their press release was mainly about claiming to add $70 million to its war chest from undisclosed existing and new investors, but they also mention a decision to have a 20% reduction of total worldwide headcount. The news was something their President was apparently thrilled to announce.

ONE Championship Adds US$70 Million To Its War ChestExisting And New Institutional Investors Participate

The largest global sports media property in Asian history, ONE Championship (ONE), today announced that it has added US$70 million to its war chest, bringing total capital to US$346 million. ONE Championship has also streamlined operations, including a 20% reduction of total worldwide headcount.

Hua Fung Teh, Group President of ONE Championship, stated: I am thrilled to announce that ONE Championship closed another round of funding a few weeks ago with existing institutional investors as well as a new institutional investor. I am full of gratitude for this strong vote of confidence amidst the worst global economic crisis in 100 years. With 9 figures of cash on the balance sheet and a streamlined organization, ONE Championship looks forward to continuing to delight our fans around the world with more heroes and new experiences for many years to come.

Apart from receiving flack from media and pundits on social media, the announcement also caught the attention of UFC President Dana White:

ONEs CEO Chatri Sityodtong also issued a separate memo to his employees that were being laid off. He spoke about a sad, heart-wrenching decision to let them go, noting how its necessary to ensure the companys longevity, while also boasting and claiming to have a strong balance sheet and a 9-digit war chest for the billion-dollar company.

Heres a snippet from the letter obtained by Tech in Asia:

The world is suffering from the single worst economic crisis in a hundred years due to Covid-19. After weeks of consultation with both our leadership team and our board of directors, I have made the decision to future-proof ONE Championship by both streamlining operations and sharpening core strategic priorities.

It is one of the most heart-wrenching decisions I have ever had to make in life. On the one hand, ONE has a strong balance sheet with a 9-digit war chest after todays new funding announcement. It puts us in the perfect position to continue aggressively building Asias largest global sports media property. On the other hand, these extraordinary times for the world require unusual prudence to protect our company and to ensure its longevity for many years to come. With the decision to sharpen our focus around core strategic priorities, ONE will undergo a 20% reduction in total worldwide headcount.

Josh Gross also spoke about the announcement, reporting that the layoffs go far beyond the 20% that ONE announced, with a figure closer to 50% - 60% of its workers, which includes all freelance contractors.

ONE spoke about COVID-19 and the economic crisis being the major reason for these layoffs. Like many companies, the MMA promotion has indeed been hit hard by the pandemic, and they havent hosted an event since February. That being said, their financial struggles date back years now.

As Bloody Elbow reported previously, documents that ONE themselves have filed with the Singapore government show massive losses that have increased each year. In 2018 alone, the company had losses of almost $59 million, with accumulated losses have amounted to a whopping $126 million.

Read the rest here:
ONE Championship lays off sizable chunk of workforce to ensure its longevity - Bloody Elbow

Read More...

The Aunt Jemima and Uncle Ben brands marketed racism – Los Angeles Times

June 18th, 2020 8:50 am

Aunt Jemima, the long-standing brand that finally was put to rest this week, has slavery in its corporate DNA.

Nancy Green, who portrayed Aunt Jemima when the character was introduced at the Worlds Columbian Exposition in Chicago in 1893, was born into enslavement six decades earlier, on a plantation in Montgomery County, Ky.

By all accounts, Greens friendly personality made her a perfect corporate mascot, launching the Aunt Jemima name and commencing more than a century of dubious marketing. She was offered a lifetime contract to continue appearing as the character, the first of numerous Black women to play the part.

Aunt Jemima, along with Uncle Ben, who it was announced this week will also be getting the heave-ho, were not responsible for creating stereotypes. Bigotry isnt new.

But the indisputably racist brands, and their bewildering longevity, speak to the power of marketing in reinforcing offensive stereotypes.

Simply put, if corporate America hadnt given its full backing to creating and promoting these images as sales tools, making them both culturally legitimate and highly profitable, its debatable whether the countrys racial divisions would have run so deep for so long.

Theres very strong support for that premise, said Jerome Williams, a business professor at Rutgers University. Corporate America perpetuated this situation.

Judy Davis, a marketing professor at Eastern Michigan University, was even more emphatic.

Advertising and marketing play an important role in selling whiteness, she told me. They have played a role in perpetuating an image that whites are superior.

Williams related how, as a kid, his mom would serve Aunt Jemima pancakes or Uncle Bens rice, and the stereotypical branding never registered as overtly racist.

It was just part of the background noise, he said. I remember watching Amos and Andy on television and laughing along with the show.

In hindsight, he realizes how much cultural damage was being done.

They were very abhorrent images, Williams said. But like many African Americans, I just accepted this as the way the world was.

Thats now changing, hopefully forever, as America and other nations shine a harsh spotlight on racial mistreatment, inequality and insensitivity following the death of George Floyd and amid a resurgence of the Black Lives Matter movement.

Quaker Oats said Wednesday its retiring Aunt Jemima after more than 130 years of pitching the brand.

As we work to make progress toward racial equality through several initiatives, we also must take a hard look at our portfolio of brands and ensure they reflect our values and meet our consumers expectations, the Pepsi-owned company said in a statement.

Mars, owner of the Uncle Bens brand, quickly followed suit, declaring that the time has come to change the products brand identity.

Now is the right time to evolve the Uncle Bens brand, including its visual brand identity, which we will do, the company said. We dont yet know what the exact changes and timing will be, but we are evaluating all possibilities.

These are laudable moves. But its hard not to wonder if theyre less an an indication of corporate enlightenment and more an awareness that theres no longer money to be made perpetuating archaic and ugly stereotypes.

When it starts affecting corporate profits, thats when it starts having an impact, Williams said of criticism from consumers.

The Aunt Jemima brand has long reflected the values of a less-woke time. Case in point, a magazine ad from 1938 that depicted the white Jones family lamenting the sorry state of Moms pancakes.

And theres Aunt Jemima, in full Mammy regalia, standing in the window declaring, Dey sure needs me in dis house!

Marketing that way may not make people prejudiced. But it lends a corporate seal of approval to such thinking.

Branding is incredibly powerful. It can teach the world to sing and enjoy a bottle of Coke. And it can promote a smug sense of white superiority.

Once something is seen as normative, its typically not questioned and taken for granted, said Sonya Grier, a marketing professor at American University. Like fish in water. And this would allow such stereotypes to be perpetuated consciously or unconsciously in society.

Seeing Aunt Jemima on a box of pancake mix, she said, drives home the idea that a Black woman belongs in the kitchen as a servant or caretaker.

The lack of discussion, especially cross-race discussion of these issues traditionally, doesnt allow for the stereotypes to be challenged on a personal individual level, Grier said.

It goes even deeper than that.

While brands such as Aunt Jemima and Uncle Ben cant solely be blamed for systemic racism, by using these stereotypical icons to represent their brands they are giving credence to such stereotypes on a global platform, said Monique Bell, an associate professor of marketing at Fresno State.

Black people, and other underrepresented groups, already face implicit biases, and these representations only encourage prejudice and further dehumanization, she said.

Recently, its felt like every company under the sun has wanted to demonstrate its commitment to racial harmony and diversity.

Some of these declarations are undoubtedly sincere and aim to promote positive change. Others may be little more than me-too pandering.

Im a little skeptical, said Kevin Thomas, an assistant professor of multicultural branding and strategic communication at Marquette University. I believe its more of a calculation at this point on the part of marketers.

Well see.

If your company is committed to change, it cant just be about changing the symbolism, said Davis at Eastern Michigan University. Dropping certain names and imagery is a start, but theres a lot more companies can do.

It could take generations, in fact, for the influence of decades of racially questionable marketing to be undone.

Davis said that when she first heard the news about Aunt Jemima, she felt gratified. Then she made herself some pancakes.

They werent Aunt Jemima, but the connection was made.

Brands are mighty things. And they must not be tolerated when they do wrong.

Read more:
The Aunt Jemima and Uncle Ben brands marketed racism - Los Angeles Times

Read More...

Higher Compliance With Mediterranean And Plant-Based Diets Reduce Heart Disease Risk Up To 21% – International Business Times

June 18th, 2020 8:50 am

KEY POINTS

Plant-based diet plans like the Mediterranean diet reduceheart disease risk by nearly 20%, according to recent research.

The experts at the Harvard T.H. Chan School of Public Health reported that people who followed the Mediterranean diet, Greek and Italian cuisine-based fight-and plant-based meals, or other plant-based diets had a 14-21% lower risk for cardiovascular diseases, depending on how well they adhered to it.

Higher compliance with a healthy eating plan was linked to a 10-20% reduced risk of heart diseases, according to the researchers.

We found that following a variety of healthy eating patterns confers significant health benefits in reducing the risk of cardiovascular disease," Dr. Frank B. Hu, the study author, professor, and chair of the Department of Nutrition at Harvard T.H. Chan School of Public School told UPI.

These heart-healthy diets share common characteristics such as higher consumption of fruits, vegetables, whole grains, legumes and nuts, and lower consumption of red and processed meats and added sugar," Hu told UPI.

The Study:

The researchers tracked the heart health of 165,794 women and 43,338 men for nearly 32 years. None of them had any history of heart disease. They evaluated the effects of four different dietary approaches on heart disease risk using several measures of adherence including the following:

Key Findings:

The researchers highlighted the fact that there is no magic bullet diet to health and longevity and that there is no such thing called a magic diet solution. They recommend consuming a variety of healthy foods in flexible ways and follow a healthy eating pattern according to each persons health needs, food preferences, as well as, cultural traditions.

mediterranean diet for longevity Photo: aytalina - Pixabay

Read this article:
Higher Compliance With Mediterranean And Plant-Based Diets Reduce Heart Disease Risk Up To 21% - International Business Times

Read More...

Therapeutic Options for Peripheral Neuropathy in Parkinson Disease – Neurology Advisor

June 18th, 2020 8:49 am

Peripheral neuropathy is frequently seen in patients with Parkinsons disease (PD) and may increase the functional disability in these individuals. A review article published in Neurological Sciences discussed the etiology of peripheral neuropathy in the context of PD.

Previous studies have shown that peripheral neuropathy can adversely affect the lives of patients with PD. As limited data are available on small fiber neuropathy (SFN) and effective treatments for peripheral neuropathy in PD, the current review focused on the etiology, pathological mechanisms, subtypes, and management of the neurological problem in PD.

The exact pathogenic mechanism of neuropathy in PD is not entirely clear and there are many potential factors involved in the disease process, including medication, mitochondrial dysfunction, oxidative stress, and genetic susceptibility.

Diagnosis

The diagnosis is based on clinical findings along with nerve conduction studies and electromyography. As some neuropathies may present with normal findings on peripheral nerves testing, a thorough patient history is vital.

The initial investigation of peripheral neuropathy often includes glucose tolerance testing, fasting glucose levels, measurement of vitamin B12, methylmalonic acid (MMA), homocysteine (Hcy), and serum protein electrophoresis.

The diagnosis of SFN is commonly difficult to be made on the basis of peripheral nerve testing and clinical criteria are more important. Intraepidermal nerve fiber density in skin biopsy or analysis of quantitative sensory testing can help in establishing the diagnosis.

Additional tools that may aid in the diagnosis and severity assessment of SFN include autonomic testing utilizing a variety of reflex tests, intraepidermal electrical stimulation tests, corneal confocal microscopy, and microneurography.

Parkinson Disease Treatment and Neuropathy

Levodopa, the gold standard treatment for PD, may play an important role in the development of peripheral neuropathy . Long-term use of levodopa can lead to increased levels of Hcy and MMA which have been linked to neuropathy, as well as increased risk for cardiovascular diseases, neurodegenerative diseases, and neural tube defects. While many studies have pointed at B12 deficiency as the potential cause for levodopa-associated neuropathy, others suggested that folate deficiency is a more important cause.

As not all patients taking levodopa develop neuropathy, experts have suggested there may be a genetic susceptibility for the development of neuropathy in some patients. Potential candidate genes involved in PN with PD may be the parkin or MTHFR genes.

Levodopa-carbidopa intestinal gel (LCIG) are additional treatment options that were found to be associated with peripheral neuropathy. Studies have suggested a higher incidence of neuropathy in PD patients treated with duodopa or LCIG. While limited data exist on the risk for SFN, there are reports suggesting an association between LCIG treatment with neuropathy of small fibers.

Administration of catechol-O-methyltransferase (COMT) inhibitors may attenuate the levodopa-induced increase in plasma Hcy and MMA levels. However, due to the limited available data, more studies are required to better understand the efficacy of COMT inhibitors in preventing peripheral neuropathy.

Treatments of Peripheral Neuropathy

The data on treatment of peripheral neuropathy in PD remain limited and additional studies are needed to explore the benefits of cobalamin injections with folate supplements and COMT inhibitors, especially in levodopa-treated patients. Novel treatment options include electromagnetic and laser therapy.

At this point in time, COMT inhibitors, such as entacapone, are the main treatment options for peripheral neuropathy. One study has shown that the addition of COMT inhibitors may improve levodopa-associated neuropathy. However, as COMT inhibitors were not found to be effective against peripheral neuropathy secondary to causes other than levodopa exposure, other therapeutic options are needed.

Combination of vitamin B12 and methylcobalamin is recommended by some experts in the field and there are reports this may improve pain and paresthesia, but most of the data are based on studies in patients with diabetic neuropathy.

Several enzymes and genetic markers were suggested as therapeutic targets for peripheral neuropathy and have shown promising results. Furthermore, monoclonal antibodies may prove to be useful, as there are reports from patients with malignant tumors in which the combination of bendamustine-rituximab was found to alleviate immune-mediated neuropathies. Early reports have suggested a potential role for ultrasound guided vitamin B12 injections.

Future studies should investigate the toxic effects of elevated Hcy and MMA levels in patients with PD along with viable treatment options that include vitamin B12 and folate therapy. Large scale studies are required in order to understand the role and efficacy of COMT-Is along with other IPD interventions in [peripheral neuropathy], concluded the investigators.

Reference

Paul DA, Qureshi ARM, Rana AQ. Peripheral neuropathy in Parkinsons disease [published online May 1, 2020]. Neurol Sci. doi:10.1007/s10072-020-04407-4

Continue reading here:
Therapeutic Options for Peripheral Neuropathy in Parkinson Disease - Neurology Advisor

Read More...

COVID 19 Impact on Neuropathy Pain Treatment Market 2020 Industry Size, Share, Applications, Manufacturers and Forecasts to 2026 – Farmers Ledger

June 18th, 2020 8:49 am

Neuropathy Pain Treatment Market 2020 Industry increasing incidence of neuropathic pain caused by damage or disease affecting the somatosensory nervous system. Growing awareness among patients and increase in the demand for generic drugs boost the market growth. However, severe side effects of opioids and steroids and rising costs of branded drugs might hamper the market growth.

For Sample Copy of this Report @https://www.orianresearch.com/request-sample/956157

Neuropathy Pain Treatment Marketreport offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures. On the basis of product, this report displays the cost structure, sales revenue, sales volume, gross margin, market share and growth rate.

Report Covers Industry Segment by Manufacturers:

Report Covers Market Segment by Types:

Global Neuropathy Pain Treatment Industry 2020 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Order Copy of this Report @https://www.orianresearch.com/checkout/956157

Report Covers Market Segment by Applications:

Key Benefits of the Report:

Target Audience:

Inquire more about Neuropathy Pain Treatment Market report @https://www.orianresearch.com/enquiry-before-buying/956157

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics, capacity Types, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the

Key Industry Participants (KIPs) which typically include:

Table of Content

1 Executive Summary

2 Methodology And Market Scope

3 Neuropathy Pain Treatment Market Industry Outlook

4 Neuropathy Pain Treatment Market By End User

5 Neuropathy Pain Treatment Market Type

6 Neuropathy Pain Treatment Market Regional Outlook

7 Competitive Landscape

End of the report

Disclaimer

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

See the original post here:
COVID 19 Impact on Neuropathy Pain Treatment Market 2020 Industry Size, Share, Applications, Manufacturers and Forecasts to 2026 - Farmers Ledger

Read More...

Chemotherapy Induced Peripheral Neuropathy Treatment Market to witness an impre – News by aeresearch

June 18th, 2020 8:49 am

The research report on Chemotherapy Induced Peripheral Neuropathy Treatment market Size provides a thorough assessment of this business vertical. As per the study, the market is predicted to accumulate significant revenues and showcase a substantial growth rate during the estimated timeframe.

The Chemotherapy Induced Peripheral Neuropathy Treatment market report is a thorough investigation of the industry in terms of consumption and production. The report, based on the production facet, encompasses details regarding the manufacturing structure and profit margins of the renowned manufacturers. The price incurred by the companies to produce, store, and sell one unit of a product across the various geographies over the analysis period are also included in the study.

Speaking of the consumption aspect, the study details the consumption value and consumption volume of the products in question. Data pertaining to the individual sales price along with the import and export patterns spanning various territories are delivered in the report. Additionally, the report also predicts the production and consumption patterns over the assessment period.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/219125

Key pointers from the competitive landscape:

An outline of the regional landscape:

A brief overview of the product spectrum:

A summary of the application terrain:

In conclusion, the report evaluates the Chemotherapy Induced Peripheral Neuropathy Treatment market through multiple classifications and provides thorough information about the upstream raw materials, downstream buyers, and distribution channels established by the various competitors. More importantly, a study of recent market trends, drivers, challenges, and opportunities shaping the profitability graph of the industry are duly presented in the report.

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/219125

Originally posted here:
Chemotherapy Induced Peripheral Neuropathy Treatment Market to witness an impre - News by aeresearch

Read More...

Are Trump’s Problems with Walking, Drinking Water Due to Hydroxychloroquine? – American Council on Science and Health

June 18th, 2020 8:49 am

As a vascular surgeon, I am well acquainted with what we call gait disturbances, an abnormal walk. I am sure many of you have seen individuals who have suffered from a stroke with partial loss of their leg, which results in a walk that is less fluid.

There are many diagnostic possibilities responsible for a change in our gait. I am, unfortunately, most familiar with structural alterations, e.g., loss of a portion of the foot, or unequal length of limbs. There can be issues related to injury;think of how we might limp after injuring our knee. And there can be neurologic causes, related to nerve injury, that leave the muscles weaker or altering proprioception the sense of the position of the body in space, which is sensory feedback necessary for balance.

In watching the video of President Trump walking down the ramp, he does seem to be favoring one leg. To be fair, his explanation that is was a slippery incline may indeed be true.

But let's now consider the video of him pausing his speech to drink a bit of water. In the video, the president raises a glass, but he can't quite lift it to his mouth. He tilts his head down to get closer to the glass before using his left hand to fully raise the glass to his lips. From a diagnostic point of view, that changes the differential. Becausewhile the gait disturbance has multiple causes, the lifting of the glass suggests a problem of muscular strength.*

So now, we have issues with two sets of muscles:the legsand arms. It would be odd to have an injury that involved two areas not be reported, especially involvingthe president. The same holds for structural problems, and that moves neuropathy up the differential list. What could be the source of a new-onset neuropathy? I know little of the presidents medical status. That is, except for one, perhaps salient fact:he said he has been taking hydroxychloroquine.

Physicians have rightly been concerned about the cardiac effects of this medication on the hearts rhythm. But hydroxychloroquine has some other, less frequently cited adverse effects. If you read the FDA requiredpackage insertunder adverse effects, here is what you will find:

Musculoskeletal and connective tissue disorders: Sensorimotor disorder, skeletal muscle myopathy orneuromyopathy leading to progressive weakness and atrophy of proximal muscle groups, depression of tendon reflexes and abnormal nerve conduction. [Emphasis added]

Proximal muscles are those closest to our body, like the muscles of the upper arm that raise the arm and hand. Or the muscles of the thigh that are actively involved in all phases of walking. It is not an overly common adverse side effect.It is probably relatively rare, but a quick search uncovered areviewof 10 cases of hydroxychloroquine associatedneuromyopathy.

Again, let me emphasize that I am not attempting to diagnose an illness without performing both a careful history or physical examination. I am trying to point out a fallacy in the therapeutic use of medications. as there is always a tradeoff between benefits and risk. Always. In reporting on the presidents decision to treat himself with hydroxychloroquine on May 18, the New York Times reported, Mr. Trump continued, explaining that his decision to try the drug was based on one of his favorite refrains: What do you have to lose?

What indeed? It would be ironic that the drug President Trump described as a game-changer might instead turn out to be a gait-changer.

Note

*This, by the way, is a reasonable example of Bayesian thinking, where I adjust my original differential (probabilities) based on further information.

The rest is here:
Are Trump's Problems with Walking, Drinking Water Due to Hydroxychloroquine? - American Council on Science and Health

Read More...

Diet and exercise are first prescription to try for prediabetes – STLtoday.com

June 18th, 2020 8:49 am

Your husband is at risk, and the fact that the symptoms are recent means he should look at this as a wake-up call. Changing his lifestyle dramatically now can not only lead to improvement in symptoms (or at least they wont get worse), but it will also reduce his risk of heart attack and stroke.

There are many places to get help: His doctor, a registered dietitian nutritionist and a diabetes nurse educator all are excellent potential sources of information, but he has to make the decision to start the lifestyle change.Vitamins do not help diabetic neuropathy. If he can start making the changes, I hope he will find, as most people have, that his quality of life and sense of well-being are so much better that he will not want to stop his healthier lifestyle. Medications may be helpful, but the primary treatment is diet and exercise.

Dear Dr. Roach My wife smoked for many years and finally quit with the help of nicotine gum that is 4 milligrams each. Since quitting almost 20 years ago, she continues to use about 12 pieces of nicotine gum per day. Does ingesting this much nicotine in this manner put her at risk for developing some type of cancer from the nicotine? T.D.

Answer No, nicotine is not carcinogenic, that is to say cancer-causing. In large doses, it is dangerous, but the doses she is taking are not at least, for a person used to them. Early signs of nicotine toxicity are excess salivation, nausea and vomiting.

Visit link:
Diet and exercise are first prescription to try for prediabetes - STLtoday.com

Read More...

Roach: Diet and exercise are first prescription to try for prediabetes – LubbockOnline.com

June 18th, 2020 8:49 am

DEAR DR. ROACH: My husband is a 50-year-old prediabetic who has recently experienced burning feet. He refuses to think it's his high-carb diet (bread three times a day, chips, ice cream) and instead thinks he just needs some vitamins for foot pain. Could you please explain why and how what he eats affects everything he's experiencing? -- Anon.

ANSWER: Diabetic neuropathy is a condition found in people who have had diabetes for years. It causes different symptoms in different people, but pain (often burning in character) and numbness are most common. The underlying cause is uncertain, but seems to be a combination of factors leading to nerve damage.

Prediabetes, often along with the other components of metabolic syndrome -- including high blood pressure, excess abdominal fat and high cholesterol or triglycerides -- may also bring on a neuropathy with very similar symptoms. Other causes, especially vitamin B12 deficiency, are appropriate to evaluate before determining the condition is most likely due to diabetes or prediabetes.

There are no specific treatments for the neuropathy, although there are medications to ease symptoms. Treatment of the underlying metabolic syndrome is therefore of the utmost importance, and the two most important treatments are diet and exercise. Avoiding simple carbohydrates, such as found in bread and chips, or the sugars in ice cream, is paramount. Regular exercise has an independent effect that adds to the effectiveness of the dietary changes.

Your husband is at risk, and the fact that the symptoms are recent means he should look at this as a wake-up call. Changing his lifestyle dramatically now can lead not only to improvement in symptoms (or at least they won't get worse), but it will also reduce his risk of heart attack and stroke.

There are many places to get help: His doctor, a registered dietitian nutritionist and a diabetes nurse educator all are excellent potential sources of information, but he has to make the decision to start the lifestyle change. Vitamins do not help diabetic neuropathy. If he can start making the changes, I hope he will find, as most people have, that his quality of life and sense of well-being are so much better that he will not want to stop his healthier lifestyle. Medications may be helpful, but the primary treatment is diet and exercise.

DEAR DR. ROACH: My wife smoked for many years and finally quit with the help of nicotine gum that is 4 milligrams each. Since quitting almost 20 years ago, she continues to use about 12 pieces of nicotine gum per day. Does ingesting this much nicotine in this manner put her at risk for developing some type of cancer from the nicotine? -- T.D.

ANSWER: No, nicotine is not carcinogenic, that is to say cancer-causing. In large doses, it is dangerous, but the doses she is taking are not -- at least, for a person used to them. Early signs of nicotine toxicity are excess salivation, nausea and vomiting.

There are many toxic substances in tobacco, some of which are cancer-causing. The tobacco does not need to be burned; chewing tobacco and snuff increase the risk of oral cancer. About half of all people who smoke will die because of smoking-related illness. Even one cigarette a day has significant long-term health risks.

Although it's not ideal that she continues to use nicotine gum (and it's not cheap), there is no doubt that the gum is much, much safer for her than continuing to smoke.

Readers may email questions to ToYourGoodHealth@med.cornell.edu. (c) 2020 North America Syndicate Inc.

Originally posted here:
Roach: Diet and exercise are first prescription to try for prediabetes - LubbockOnline.com

Read More...

Global Regenerative Medicine Market (2020 to 2024) – Size & Forecast with Impact Analysis of COVID-19 – ResearchAndMarkets.com – Business Wire

June 18th, 2020 8:48 am

DUBLIN--(BUSINESS WIRE)--The "Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

This report provides an in-depth analysis of the global regenerative medicine market with description of market sizing and growth. The analysis includes market by value, by product, by material and by region. Furthermore, the report also provides detailed product analysis, material analysis and regional analysis.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global regenerative medicine market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Regenerative medicines emphasise on the regeneration or replacement of tissues, cells or organs of the human body to cure the problem caused by disease or injury. The treatment fortifies the human cells to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells that can be used in regenerative medicine: somatic stem cells, embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

The regenerative medicine also has the capability to treat chronic diseases and conditions, including Alzheimer's, diabetes, Parkinson's, heart disease, osteoporosis, renal failure, spinal cord injuries, etc. Regenerative medicines can be bifurcated into different product type i.e., cell therapy, tissue engineering, gene therapy and small molecules and biologics. In addition, on the basis of material regenerative medicine can be segmented into biologically derived material, synthetic material, genetically engineered materials and pharmaceuticals.

The global regenerative medicine market has surged at a progressive rate over the years and the market is further anticipated to augment during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease and surging obese population.

Though, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: legal obligation and high cost of treatment. Whereas, the market growth would be further supported by various market trends like three dimensional bioprinting , artificial intelligence to advance regenerative medicine, etc.

Market Dynamics

Growth Drivers

Challenges

Market Trends

Companies Profiled

For more information about this report visit https://www.researchandmarkets.com/r/ufteqn

Read more from the original source:
Global Regenerative Medicine Market (2020 to 2024) - Size & Forecast with Impact Analysis of COVID-19 - ResearchAndMarkets.com - Business Wire

Read More...

Regenerative Medicine Market Demand with Leading Key Players and New Investment Opportunities Emerge To Augment Segments in Sector By 2030 – Cole of…

June 18th, 2020 8:48 am

Market Industry Reports (MIR) has published a new report titled Regenerative Medicine Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2030. According to the report, the global regenerative medicine market was estimated to be over US$ 13 billion in 2019. It is anticipated to grow at a CAGR of 23.2%from 2019 to 2030.

Some of the prominent players in the global regenerative medicine market include:

Novartis AG,Integra LifeSciences Corporation,Vericel Corporation,MiMedx, Stryker,Spark Therapeutics, Inc.,Osiris Therapeutics, Inc.,Kite Pharma,Organogenesis Inc. and MEDIPOST among others.

Click Here to Get Acess of Sample Pages @https://www.marketindustryreports.com/pdf/254

Scope of Report:

The significant growth of the market can be attributed to increasing prevalence of chronic as well as genetic disorders followed by increasing demand of medicines and therapies that can help cure and prevent these disorders. Moreover, increasing private and government investments for research & development of regenerative medicines are anticipated to boost the regenerative medicine market over the forecast period. To obtain better insights regarding the market scenario, prominent players are increasingly focusing on mergers, acquisitions or collaborations with smaller regenerative medicine companies. For instance, in Jan 2020, Amgen announced a strategic collaboration with BeiGene a biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer. This strategic collaboration will enable Amgen to expand its oncology presence in China.

In recent years, prevalence and incidences of chronic infectious diseases as well as genetic disorders is increasing. For instance, according to American Cancer Society, in 2019, there were around 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States. Such high incidence rates are thus increasing the demand of medicines that can help to prevent or cure such diseases. Such factors are expected to play a pivotal role in fueling the growth of the market during the forecast period.

Segmentation:

Regenerative Medicine Market By Type:Cell-Based Immunotherapy & Cell Therapy Products,Tissue-Engineering Products andGene Therapy Products

Application:Musculoskeletal Disorders,Oncology,Ocular Disorders,Wound Care and Diabetes

To Avail Limited Offers Get Interesting Discount @https://www.marketindustryreports.com/discount/254

This Regenerative Medicine market report holds answers to some important questions like:

1. What is the size of occupied by the prominent leaders for the forecast period, 2020 2030? What will be the share and the growth rate of the Regenerative Medicine market during the forecast period?2. What are the future prospects for the Regenerative Medicine industry in the coming years?Which trends are likely to contribute to the development rate of the industry during the forecast period, 2020 2030?3. What are the future prospects of the Regenerative Medicine industry for the forecast period, 2020 to 2030?4. Which countries are expected to grow at the fastest rate?5. Which factors have attributed to an increased sale worldwide?6. What is the present status of competitive development?

Table of Content

1 Introduction of Regenerative Medicine Market1.1 Industry Overview1.2 Scope of the Report1.3 Assumptions

2 Executive Summary

3 Research Framework by Market Industry Reports3.1 Data Mining3.2 Data Validation3.3 Primary Interviews3.4 Data Sources List

4 Regenerative Medicine Market Overview4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Limitations4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Regenerative Medicine Market, By Product TypeOverview of Regenerative Medicine Market

6 Regenerative Medicine Market, By ApplicationOverview of Regenerative Medicine Market

7 Regenerative Medicine Market, By End UserOverview of Regenerative Medicine Market

To Know More Information Buy this Full Report @https://www.marketindustryreports.com/checkout/254

About Us

Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the caliber of market dynamics & hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.

Contact Us

Email: [emailprotected]Phone: +1 347 767 5477 ( US ) + 91 8956 767 535 ( IN ) + 44 131 463 4161 ( UK )Website:https://www.marketindustryreports.com

Read more:
Regenerative Medicine Market Demand with Leading Key Players and New Investment Opportunities Emerge To Augment Segments in Sector By 2030 - Cole of...

Read More...

Regenerative Medicine Market 2020, by Brands, Prices, Sales, Distribution Channels, Production, Demand and Investment Opportunities to 2025 – Cole of…

June 18th, 2020 8:48 am

Global Regenerative Medicine market covers a detailed analysis of the market appearances, segmentation, size and progress, market shares, provincial collapses, competitive background, tendencies and several growth strategies for this Regenerative Medicine market. Likewise, the market appearances section of this study describes and defines the complete overview of the Regenerative Medicine market. The global Regenerative Medicine market report extent segment offers the market revenues, covering both the momentous growth of the industry and anticipating the upcoming market revenue. In addition, global market separations break down into the key sub-areas which gives a better idea about the market size.

Get Sample Copy of this Report: https://www.adroitmarketresearch.com/contacts/request-sample/52

Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. Some of the important aspects analysed in the report includes market share, production, key regions, revenue rate as well as key players. This Regenerative Medicine market report also provides the readers with detailed figures at which the Regenerative Medicine market was valued in the historical year and its expected growth in upcoming years. Besides, analysis also forecasts the CAGR at which the keyword is expected to mount and major factors driving markets growth.

In addition, the report include deep dive analysis of the market, which is one of the most important features of the Regenerative Medicine market. Furthermore, the need for making an impact is likely to boost the demand for the experts which are working in the market. Moreover, an in depth analysis of the competitors is also done to have an estimate for the Regenerative Medicine market. Moreover, the report provides historical information with future forecast over the forecast period. Production, market share, revenue rate, key regions and major vendors are some of the vital aspects analysed in the report. This report on Regenerative Medicine market has been made in order to provide deep and simplified understanding of the market to its end users. The study on global Regenerative Medicine market, offers profound understandings about the Regenerative Medicine market covering all the essential aspects of the market.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/regenerative-medicine-market

Potential consumers, market values, and the future scope for the Regenerative Medicine market are explained thoroughly to the users in this report. The key players of Regenerative Medicine industry, their product portfolio, market share, industry profiles is studied in this report. Adaptation of new ideas and accepting the latest trends are some the reasons for any markets growth. The Global Regenerative Medicine market research report gives the deep understanding about the regions where the market is impactful. It also elaborates the big and small vendors working actively all over the globe.

Regenerative Medicine market report studies the current state of the market to analyse the future opportunities and risks. Regenerative Medicine market report provides a 360-degree global market state. Potential consumers, market values, and the future scope for the Regenerative Medicine market are explained thoroughly to the users in this report.

For Any Query on the Regenerative Medicine Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/52

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read the original:
Regenerative Medicine Market 2020, by Brands, Prices, Sales, Distribution Channels, Production, Demand and Investment Opportunities to 2025 - Cole of...

Read More...

Six tales from the trenches of running a startup – MIT Technology Review

June 18th, 2020 8:48 am

Our company has built a platform to produce high-quality cells and tissues for regenerative medicine. That pursuit involves multiple disciplines, which means everyone here is an expert in a different language. Some of us are fluent in stem-cell biology, others in optical engineering, others in machine learning. When we started the company it wasnt possible to do biology and engineering under the same roof. When we finally moved into a shared space we were able to learn each others lexicons, and we became more strongly aligned. And now that were all working separately, the bonds created in that process have helped us deal with things. We cant discuss technical details at our desks anymore, but weve learned new ways of working together. Its important to stay in sync as a team, and in a covid-19 world thats never felt more true.

TIM O'CONNELL

Founded Blendoor, a job-search platform that hides candidates names and photos in the initial stages to reduce unconscious bias.

I started coding at 13, and that has gotten me pretty far in my career (Stanford, MIT, Microsoft). I once viewed humanities and social science education as nice-to-haves but not need-to-haves. It wasnt until I came face to face with the harsh realities of inequity and the paradox of meritocracy that I realized that artificial intelligence is far from solving many of our most challenging problems as a human race (for example, xenophobia, sexism, racism, homophobia, impostor syndrome, and unconscious bias).

The externalities that influence creativity, adoption, and scale are often more important than the innovation itself. To be a successful innovator one has to be really in tune with whats happening in the world on a global scale (or be really lucky, or better yet both). Venture capital has shortened the learning curve for some innovators, but bias has limited access to venture capital for many. Unconscious bias is like an odorless gasits imperceptible to most, but pervasive and deadly.

To optimize the innovation ecosystem, institutions must invest more in leveling the playing field. Today and for much of the documented past, innovation has been reserved for the children of middle- and upper-class parents. (Research the founders of companies valued at over $1 billion.) We laud the proverb Necessity is the mother of invention, but the people who grow up needing the most, independent of their intelligence, are often left out of the innovation game. As with all games, the best players emerge when the barriers to entry are low, the rules/standards are equally enforced, and there is high transparency across the board.

Audre Lorde once wrote: The masters tools will never dismantle the masters house.

I am a short, melanin-enriched, queer female on planet Earth. In some ways its easier to be innovative when youre invisible, but at some point, you need tools to scale: capital, team, mentorship. The one thing I know now that I wish I had known earlier is that my path toward getting the tools I need looks a lot different from the paths of others. Its not better nor worsesimply different. The hardest part is carving it out. Now that I know my path isnt blockedrather, it just didnt existIm way better equipped to win.

COURTESY PHOTO

Founded DotLab, which makes diagnostic tests focused on womens health.

About a decade ago I worked at the White House Office of Science and Technology Policy, whose goal was to speed up the commercialization of technologies being developed in federally funded labs. While there I saw that some of the most important work done by the government involved things the media paid no attention tofor example, the way it could use investments in research and development to fuel private--sector innovation.

In 2009, the Obama administration released the Strategy for American Innovation. The idea behind it was to establish the critical nature of federal government support for R&D. In particular it stressed the spillover effects, or the idea that investments in such research end up being beneficial to people unrelated to the original investment. Or to put it another way, R&D investment is a public good. Analyses at the time suggested that in order to produce economic growth we should be doubling or quadrupling our R&D investments. Instead that spending has since been slashed, especially in basic research.

President Obama also launched a Lab to Market Initiative meant to speed the path to market for technologies stemming from government--funded research. There were also pilot programs designed to increase the use of government-funded R&D facilities by entrepreneurs, create incentives to commercialization, and improve, among other things, the impact of the Small Business Innovation Research (SBIR) program.

My own company, DotLab, ended up being a beneficiary. We develop novel molecular diagnostic tests for prevalent yet underserved diseases affecting womens health. Its notoriously difficult for this field of early--stage diagnostics to attract private investment, because of unclear regulatory pathways, low reimbursement rates, or resistance to change among physiciansor all of the above. Many promising diagnostic technologies never make it to patients because its so hard for these types of companies to get financing. A grant from the SBIR was critical to our early success. I cant be sure that wed be here today without it.

COURTESY PHOTO

Founded Ubiquitous Energy, which makes transparent solar cells that can be put on windows or device screens.

I used to imagine innovators as individuals, as most people probably dothe genius inventor divining solutions in a lab or garage. But this picture that people have is not only wrong; it hinders our ability to innovate effectively.

Eight years ago I cofounded Ubiquitous Energy, a company based on an innovation Id helped to launch from an MIT laba transparent solar cell that promised new ways of deploying solar technology, like windows that generate energy or consumer devices powered by their own displays. I learned that in the messy, scrappy world of tech startups, the key to innovation is to make it a team sport.

Taking any innovation from the lab to commercial reality requires engaging with all sorts of people. You need to work with engineering, R&D, business development, and sales teams, as well as investors, advisors, and customers. By thoughtfully designing teams and carefully tending to the connections among them, you ensure that innovation doesnt happen in a vacuum. If you isolate the engineering team you risk creating an innovative technology that doesnt have a customer. If you listen only to the customer you might conceive of a product that cant practically be made. Neglect investors and you can find yourself with a business plan that nobody wants to fund.

Working among people with competing priorities takes more effort. It means encouraging communication so theyre aware of each others needs as they generate new ideas. You have to find a way to invite these ideas in, make it okay for people to disagree respectfully, and encourage the flow of ideas among the various groups. You need each person to focus on his or her task, but not so much that it creates boundaries and kills any sense of creativity in the group.

Ive found that viewing innovation as a team sport instills a creative culture that makes an organization better. The innovations that result are far greater than anything that might have come from any one person operating independently.

CHRIS SCIACCA / IBM RESEARCH

Founded Somalias first incubator and start-up accelerator; now at IBM Research.

People tend to think innovation can be neatly placed into two categories: incremental or disruptive. They also assume that the only category that really matters is the disruptive kind, where you dramatically transform markets or introduce a novel product. And yes, disruptive innovations in CRISPR, quantum computing, or batteries are undoubtedly worth the headlines.

But Ive learned that there is immense value in incremental innovation. When you improve an existing product to cut costs, or when you make that product more efficient or user friendly, thats what pays the bills. And in fact those little innovations can give you the needed tailwind to go after the disruptive ideas, which can take years to incubate and bring to fruition. Never underestimate the importance of incremental improvements.

TIM O'CONNELL

Cofounded Imprint Energy, which is developing thin, flexible, and safe print- able batteries.

As a CEO of a startup, you get used to hearing no. You also face an endless succession of what feel like earth--shattering crises, like nearly running out of cash, losing a key customer, discovering a widespread product failureor having to shut down operations because of a global pandemic. But it turns out that these disasters can actually be good for you. In fact, Im not sure you can innovate without them. Heres what all our crises have taught me.

Its good to be uncomfortable. We once had a key customer request a battery capability that wed never deployed before. The customer made it clear that if we couldnt develop this capability theyd be less confident in our product. We wrestled with the risks, not least of which was the potential embarrassment if we couldnt meet the customers needs. We knew wed face many technical problems with no obvious solutions if we tried to pull it off. Yet we decided to try to satisfy the customer, even if it wasnt obvious at first how we could get it done. A few weeks later we delivered something beyond what the customer had asked for, and weve since grown this capability into a powerful sales tool and potential revenue streamnot to mention it strengthened our relationship with the customer.

Short-term failure is good. A few years ago our company began to scale up our manufacturing output in response to a customers need. In the process we discovered aberrations we hadnt seen during smaller-scale production. Our team dived into failure analysis, and we finally attributed the problem to a single material within the battery. Wed used this material for years, but now we needed a replacement. Once we deployed that change, the battery quality, reliability, and manufacturability drastically improved.

Its okay to be vulnerable. One of my hardest days as Imprints CEO was the day I found out I was pregnant. We were in the middle of raising a funding round, we had begun scaling our manufacturing output, and I had been traveling nonstop for a year. Until that day, I had assumed that my role as CEO was to exude strength and confidence. With the mounting pressure I was harder on myself than I needed to be, and now I had the added stress of being pregnant. I decided to acknowledge to my team that I was overwhelmed. They rallied together and found ways to operate more efficiently and communicate more effectively, supporting me to focus my time and leverage on our most pressing goals. This gave me not only the space to plan for the companys future, but also the resiliency to prepare for my own new normal: leading while becoming a first-time mother.

Read the original:
Six tales from the trenches of running a startup - MIT Technology Review

Read More...

Agalsidase Beta BS IV Infusion [JCR] (JR-051) for Fabry Disease: Notice on the Publication of the Results of the Phase 1 and 2/3 Clinical Trials in…

June 18th, 2020 8:48 am

DetailsCategory: Proteins and PeptidesPublished on Thursday, 18 June 2020 09:51Hits: 128

June 17, 2020 I JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; JCR) announced today that the results of the phase 1 and 2/3 clinical trials of Agalsidase Beta BS I.V. Infusion [JCR] (JR-051), recombinant Agalsidase Beta, for Fabry disease have been published in the electronic edition of Molecular Genetics and Metabolism, the official journal of Society for Inherited Metabolic Disorders. This is JCRs first product for enzyme replacement therapy (ERT) for Lysosomal Storage Disorders (LSDs), also the first of the kind manufactured in Japan. Agalsidase Beta BS I.V. Infusion [JCR] has been launched since November 2018 as the first biosimilar for the treatment of rare diseases. A summary of the article is as follows.

Title: Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase I and II/III clinical studies

Digital Object Identifier: https://doi.org/10.1016/j.ymgme.2020.04.003

Summary The Phase 1 and 2/3 studies were conducted with the aim to verify clinical comparability of JR051 and an upfront biopharmaceutical (agalsidase beta). The results demonstrated that JR051 and agalsidase beta are comparable in terms of efficacy and safety.

Phase 1 study: 20 healthy adult male volunteers were administered JR-051 and agalsidase beta to confirm pharmacokinetic equivalence in a randomized, double-blind, parallel-group manner. The study demonstrated comparable pharmacokinetic profiles of JR-051 and agalsidase beta.

Phase 2/3 study: 16 patients with Fabry disease underwent treatment with agalsidase beta (1mg/kg, once every other week), then were switched to intravenous administrations of JR-051 (1 mg/kg, once every other week).

Efficacy: The 95% confidence intervals of the ratios of the GL-3 plasma concentrations (primary endpoint) during the agalsidase beta treatment, as well as those of Lyso-GL-3, to the respective plasma concentrations after 26 and 52 week-administrations of JR-051 were within pre-determined equivalence acceptability ranges.

Safety: No severe infusion associated reactions (IARs), such as anaphylactic shock, were observed. One IAR, commonly observed with the ERT for Fabry disease, was reported in a patient after JR-051 administration.

[About JCR Pharmaceuticals]

JCR is a specialty pharma company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, Contributing towards peoples healthcare through pharmaceutical products drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations.

SOURCE: JCR Pharmaceuticals

Go here to see the original:
Agalsidase Beta BS IV Infusion [JCR] (JR-051) for Fabry Disease: Notice on the Publication of the Results of the Phase 1 and 2/3 Clinical Trials in...

Read More...

Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunc | OPTH – Dove Medical Press

June 18th, 2020 8:48 am

Borja de la Sen-Corcuera,1,2 Jess Montero-Iruzubieta,3,4 Ronald M Snchez-vila,1,5 Gorka Orive,1,2 Eduardo Anitua,1,2 Manuel Caro-Magdaleno,4 Jess Merayo-Lloves5

1Biotechnology Institute (BTI), Vitoria, Spain; 2University Institute for Regenerative Medicine and Oral Implantology (UIRMI), Vitoria, Spain; 3Clnica Cartujavisin, Sevilla, Spain; 4Hospital Universitario Virgen de Macarena, Sevilla, Spain; 5Instituto Universitario Fernndez-Vega, Fundacin de Investigacin Oftalmolgica, Universidad de Oviedo, Oviedo, Spain

Correspondence: Ronald M Snchez-vilaInstituto Universitario Fernndez-Vega, Fundacin de Investigacin Oftalmolgica, Avda Dres Fernndez-Vega Num 34, Oviedo E-33012 Principado de Asturias, SpainTel +34 985240141Fax +34 985233288Email ronald.sanchezavila@gmail.com

Purpose: The objective was to evaluate the clinical results obtained from the use of immunosafe plasma rich in growth factors (isPRGF) in the treatment of patients with cicatrizing conjunctivitis (CC) who had not responded to the usual therapy.Patients and Methods: This is a retrospective study that included patients diagnosed with CC, in whom isPRGF was used in different phases (I: eye drops; II: eye drops and injectable; III: eye drops, injectable and surgical treatment) to achieve control of the inflammation. As a clinical follow-up of the patients, the better corrected visual acuity (BCVA), degree of inflammation (measured from 1 to 4), the severity of the CC, Schirmer I test, IOP and TBUT were analyzed. The adverse events were also evaluated.Results: Ten eyes (6 patients) were evaluated, 50% corresponded to StevensJohnson Syndrome and 50% to ocular mucous membrane pemphigoid. The mean age was 59.7 16.5 (39 80) years, and 50% were women. Fifty per cent of the cases were initially considered severe CC, and 10% of the cases (one eye of one patient) were considered severe CC at the end of the treatment (p = 0.046). The initial degree of inflammation was 2 in 4 eyes, 3 in two eyes, and 4 in 4 eyes, and final inflammation degree was 1 in all cases (p = 0.004). Twenty per cent of the cases achieved stability in Phase I of the treatment with immunosafe PRGF, 70% with both Phases I and II, and only one case underwent Phase III to achieve stability. The IOP improved significantly (p = 0.027) though the BCVA, TBUT and Schirmer I test showed no significant changes. The follow-up time was 23.1 6.7 (13.6 30.3) months. No adverse effects were reported.Conclusion: Treatment with PRGF technology in its injectable and topical immunosafe formulations may be a novel alternative for the treatment of patients with CC, given its complement activity modulating effect, as well as its anti-inflammatory, antifibrotic and regenerative properties.

Keywords: immunosafe plasma rich in growth factors, isPRGF, StevensJohnson syndrome, ocular mucous membrane pemphigoid, blood derivatives

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

More here:
Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunc | OPTH - Dove Medical Press

Read More...

What Is the Impact of COVID-19 on 3D Cell Culture Market During Projected Period of 2020-2026? – Cole of Duty

June 18th, 2020 8:48 am

Post COVID-19 Impact on 3D Cell Culture Market

With the emergence of the COVID-19 crisis, the world is fighting a health pandemic as well as an economic emergency, almost impacting trillions of dollars of revenues. Research Dive group of skilled analysts provide a solution to help the companies to survive and sustain in this economic crisis. We support companies to make informed decisions based on our findings resulting from the comprehensive study by our qualified team of experts.

Our study helps to acquire the following: Long-term and short-term impact of Covid-19 on the market Cascading impact of Covid-19 on 3D Cell Culture Market, due to the impact on its extended ecosystem Understanding the market behavior Pre- and Post-COVID-19 pandemic Strategy suggestions to overcome the negative impact or turn the positive impact into an opportunity Well help you fight this crisis through our business intelligence solutions.

Connect with Analyst to Reveal How COVID-19 Impacting On 3D Cell Culture Market: https://www.researchdive.com/connect-to-analyst/73

Pre COVID-19 Analysis of 3D Cell Culture Market

According to a study of Research Dive, global 3D Cell Culture market forecast shall cross $12,638.8 million by 2026, growing at a CAGR of 29.4 during forecast period.

3D Cell culture is an essential tool in clinical analysis and biological science. It has multiple applications such as in biosensors, drug screening and others. Many improvements have been made in automated high-throughput cell culture systems. Increasing demand for regenerative medicine and economic drug discovery is expected to drive the demand for the 3D cell culture market. 3D cell cultures are primarily used to observe the abnormal behavior of cells and the cell-cell interaction. Furthermore, 3D cell culture systems play a significant role in the development of precision medicine and personalized medicine. For instance, as per study of cancer researchers (University of Michigan) newly invented 3D structure could enable physicians to test medications on model tumors grown from a patients own cells. These advances are projected to boost the growth of global cell culture market. However, more complex culture system, added expenses and threats from substitutes like 2D cell cultures are projected to limit the 3D cell culture market growth.

With new advances, 3D composite scaffolds have many versatile properties. It will be tremendously useful to develop treatments for nerve disorders and spinal cord injury (SCI) by taking help of cell transplantation methodologies and biomaterials. The most remarkable advantage of 3D cell culture is, their properties can be easily adapted by modifying the structure and composition. These key factors of 3D cell culture are projected to create enormous opportunities for the growth of 3D cell culture industry.

According to Analyst Evaluation, Microchips market shall register a revenue of $2,515.5 million by the end of 2026, growing at a CAGR of 30.1% during the forecast period; this is significantly due to new advances in 3D culture organs-on-chips. Organs-on-chips allow study of human physiology and also reveal development of novel in vitro disease models. It could provide potential replacements for animals used in toxin testing and drug development. These advancements are anticipated to grow the demand of microchips in global market, and are projected to boost the global market. Scaffold-based platforms have the largest market share and this segment will register a revenue of $3,425.1 million by the end of 2026, growing at a CAGR of 28.4%. Scaffolds can be significantly used in drug development therapeutic or specialty areas; which is anticipated to fuel the of global market growth.

Download Exclusive Sample Copy of the Report at: https://www.researchdive.com/download-sample/73

Based on applications, the market is segmented into Stem Cell research, drug discovery, cancer research, and regenerative medicine. 3D cell culture market size for cancer research will generate a revenue of $4,057.1 million by 2026, growing at a CAGR of 28.5% throughout the forecast period; this is majorly due to various types of cancers such as breast cancer, lung cancer and others being dominant among the population. Cancer has a pervasive prevalence across the globe, which has led to rise in demand for cancer research, which is further attributed to boost the demand for 3D cell culture market. 3D cell culture market for regenerative medicine will register a revenue of $3,690.5 million by 2026, growing at a CAGR of 30.1%. Many developed and developing countries such as Japan is focusing more on contract manufacturing tie-ups, and continues to be a lucrative place for biotech ventures to do business. Japan is the world leader in regenerative medical products; these key strategies of the government are anticipated to spur the growth of 3D cell culture market.

3D cell culture market for biotechnology & pharmaceutical companies will register a revenue of $5,184.4 million by 2026, growing at a CAGR of 28.9% during the forecast period; this is majorly due to huge developments in the laboratory, technology and operations. Furthermore, rising pressure on sales of established treatments, rapid growth of cell therapies and focus on advanced manufacturing and technologies are the factors expected to grow the market.

North America 3D Cell Culture market size will cross $4,019.1 million by 2026, increasing at a healthy CAGR of 28.1%.

Heavy investments in research & development, high healthcare expenditure, and extensively increasing number of cancer cases are considered to be one of the driving factors that are booming the growth of North American market.

3D Cell Culture market share for Asia-Pacific region is expected to rise at a CAGR of 30.7% by generating a revenue of $3,020.7 million by 2026. The market growth in the region is increasing drug discovery initiatives among pharmaceuticals and biotechnology companies in the region. Major economies such as India, Singapore, Japan and South Korea are emphasizing more on public sector openness to partnership with established companies. For instance, leading market players such as Bayer, GlaxoSmithKline and AstraZeneca are collaborating with Singapore partners across drug discovery.

View out Trending Reports with the Impact of COVID-19: https://www.researchdive.com/covid-19-insights

The major 3D Cell Culture manufacturers include QGel SA, Hrel Corporation, SynVivo, Greiner Bio-One International, Advanced BioMatrix, Lonza, Corning Incorporated, Thermo Fisher Scientific, TissUse GmbH, 3D Biotek. Players using updated technologies for their 3D Cell Culture will have good probability of having success in the rapidly blooming market. For example, Lonza has innovated the RAFT 3D Culture System that produces hepatocytes with increased stability and stronger cytochrome responses.

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:[emailprotected]LinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

Link:
What Is the Impact of COVID-19 on 3D Cell Culture Market During Projected Period of 2020-2026? - Cole of Duty

Read More...

Nanocellulose Market to Reach USD 1.08 Billion by 2027 | CAGR:20.4% | Reports And Data – PRNewswire

June 18th, 2020 8:48 am

NEW YORK, June 17, 2020 /PRNewswire/ -- The globalNanocellulose marketis forecast to reach USD 1.08 Billion by 2027, according to a new report by Reports and Data. The market is seeing an expanded interest from the composites sector owing to its critical characteristics, including biodegradability, non-toxicity, and sustainability, along with thixotropic Nanocellulose properties. However, volatile prices of raw materials arising necessity for exploring and adopting other content as a substitute to reduce the overall cost of the operation will be hampering the demand for the market.

Cosmetics would have substantial potential for Nanocellulose across the forecast period. It is used as a synthetic covering agent for fingers, eyes, eyebrows, or eyelashes in cosmetics. The product also provides antioxidant properties and is now used in products for sun care. It is also used for wound dressings in the surgical profession and regenerative medicine. Other uses include pharmaceuticals, tobacco filter additives, computer components, electronic displays, condensers, lithium battery films, lightweight body armor, loudspeaker membranes, and ballistic glass. However, low awareness about product use and high prices may, in the coming years, somehow hamper the demand. Nano fibrillated cellulose held the highest share in the overall market in 2019.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/3207

They possess exceptional properties, including superior strength, lightweight, transparency, and rigidity, among others, which makes them viable for many commercial applications across composites, oil & gas, food & beverage, automotive, aerospace, and personal care industries. Nano-fibrillated cellulose could also be a future replacement for plastic films in composite packaging due to the low oxygen permeability. The composites segment was the largest application segment in the overall market in 2019 by volume. Nowadays, composites are used widely in many applications. It is used in refurbishments as filler stuff. End-users are increasingly concerned about the application of synthetic fillers in composites and the environmental concerns associated with that application. Thus, replacing synthetic pads with natural ones like cellulose fibers will bring many positive environmental benefits as the product offers good thermal conductivity, low density, and biodegradability, owing to increasing personal care and food & beverage industries in the area. The market in the Asia Pacific region will propel the product demand over the projected period. Countries, including China, Japan, and India, have played a significant role in enhancing the nanotech profile of the region. Japan's AIST Nanocellulose Forum, for example, is focused on strengthening cooperation between industry, universities, and government.

The COVID-19 Impact:

As the COVID-19 crisis continues to intensify, producers are quickly adapting their activity and purchasing objectives to satisfy the demands of a pandemic that has limited the need for Nanocellulose in the market. A sequence of both positive and negative shocks may arise over a few months, as producers and their vendors respond to the evolving demands of customers. The export-dependent economies in several nations look weak, with an adverse global circumstance. Global Nanocellulose markets are reshaped by the effects of this pandemic, as some suppliers are either shutting down or reducing their output, due to a lack of demand from the downstream market. Although others are getting their production suspended as a precautionary step by their respective governments to prevent the spread of the virus. In certain countries, consumers based on being more regional by looking at the magnitude of the epidemic and the consequent behavior of the national authorities themselves. Under these circumstances, market conditions of the Asia Pacific regions were quite dynamic, weakening regularly, making stabilizing themselves difficult.

To identify the key trends in the industry, click on the link below:https://www.reportsanddata.com/report-detail/nanocellulose-market

Further key findings from the report suggest

Order Now: https://www.reportsanddata.com/checkout-form/3207

For the purpose of this report, Reports and Data have segmented into the global Nanocellulose market on the basis of product, distribution channel, application, and region:

Product Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Distribution Channel Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Application Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Regional Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Browse more similar reports on Materials and Chemicalscategory by Reports And Data

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John WHead of Business DevelopmentReports And Data | Web: http://www.reportsanddata.com Direct Line: +1-212-710-1370E-mail: [emailprotected] LinkedIn | Twitter | Blogs

SOURCE Reports And Data

Continued here:
Nanocellulose Market to Reach USD 1.08 Billion by 2027 | CAGR:20.4% | Reports And Data - PRNewswire

Read More...

What are the 3D Cell Culture Market Key Insights and COVID-19 Business Impact? – 3rd Watch News

June 18th, 2020 8:48 am

Post COVID-19 Impact on 3D Cell Culture Market

With the emergence of the COVID-19 crisis, the world is fighting a health pandemic as well as an economic emergency, almost impacting trillions of dollars of revenues. Research Dive group of skilled analysts provide a solution to help the companies to survive and sustain in this economic crisis. We support companies to make informed decisions based on our findings resulting from the comprehensive study by our qualified team of experts.

Our study helps to acquire the following: Long-term and short-term impact of Covid-19 on the market Cascading impact of Covid-19 on 3D Cell Culture Market, due to the impact on its extended ecosystem Understanding the market behavior Pre- and Post-COVID-19 pandemic Strategy suggestions to overcome the negative impact or turn the positive impact into an opportunity Well help you fight this crisis through our business intelligence solutions.

Connect with Analyst to Reveal How COVID-19 Impacting On 3D Cell Culture Market: https://www.researchdive.com/connect-to-analyst/73

Pre COVID-19 Analysis of 3D Cell Culture Market

According to a study of Research Dive, global 3D Cell Culture market forecast shall cross $12,638.8 million by 2026, growing at a CAGR of 29.4 during forecast period.

3D Cell culture is an essential tool in clinical analysis and biological science. It has multiple applications such as in biosensors, drug screening and others. Many improvements have been made in automated high-throughput cell culture systems. Increasing demand for regenerative medicine and economic drug discovery is expected to drive the demand for the 3D cell culture market. 3D cell cultures are primarily used to observe the abnormal behavior of cells and the cell-cell interaction. Furthermore, 3D cell culture systems play a significant role in the development of precision medicine and personalized medicine. For instance, as per study of cancer researchers (University of Michigan) newly invented 3D structure could enable physicians to test medications on model tumors grown from a patients own cells. These advances are projected to boost the growth of global cell culture market. However, more complex culture system, added expenses and threats from substitutes like 2D cell cultures are projected to limit the 3D cell culture market growth.

With new advances, 3D composite scaffolds have many versatile properties. It will be tremendously useful to develop treatments for nerve disorders and spinal cord injury (SCI) by taking help of cell transplantation methodologies and biomaterials. The most remarkable advantage of 3D cell culture is, their properties can be easily adapted by modifying the structure and composition. These key factors of 3D cell culture are projected to create enormous opportunities for the growth of 3D cell culture industry.

According to Analyst Evaluation, Microchips market shall register a revenue of $2,515.5 million by the end of 2026, growing at a CAGR of 30.1% during the forecast period; this is significantly due to new advances in 3D culture organs-on-chips. Organs-on-chips allow study of human physiology and also reveal development of novel in vitro disease models. It could provide potential replacements for animals used in toxin testing and drug development. These advancements are anticipated to grow the demand of microchips in global market, and are projected to boost the global market. Scaffold-based platforms have the largest market share and this segment will register a revenue of $3,425.1 million by the end of 2026, growing at a CAGR of 28.4%. Scaffolds can be significantly used in drug development therapeutic or specialty areas; which is anticipated to fuel the of global market growth.

Download Exclusive Sample Copy of the Report at: https://www.researchdive.com/download-sample/73

Based on applications, the market is segmented into Stem Cell research, drug discovery, cancer research, and regenerative medicine. 3D cell culture market size for cancer research will generate a revenue of $4,057.1 million by 2026, growing at a CAGR of 28.5% throughout the forecast period; this is majorly due to various types of cancers such as breast cancer, lung cancer and others being dominant among the population. Cancer has a pervasive prevalence across the globe, which has led to rise in demand for cancer research, which is further attributed to boost the demand for 3D cell culture market. 3D cell culture market for regenerative medicine will register a revenue of $3,690.5 million by 2026, growing at a CAGR of 30.1%. Many developed and developing countries such as Japan is focusing more on contract manufacturing tie-ups, and continues to be a lucrative place for biotech ventures to do business. Japan is the world leader in regenerative medical products; these key strategies of the government are anticipated to spur the growth of 3D cell culture market.

3D cell culture market for biotechnology & pharmaceutical companies will register a revenue of $5,184.4 million by 2026, growing at a CAGR of 28.9% during the forecast period; this is majorly due to huge developments in the laboratory, technology and operations. Furthermore, rising pressure on sales of established treatments, rapid growth of cell therapies and focus on advanced manufacturing and technologies are the factors expected to grow the market.

North America 3D Cell Culture market size will cross $4,019.1 million by 2026, increasing at a healthy CAGR of 28.1%.

Heavy investments in research & development, high healthcare expenditure, and extensively increasing number of cancer cases are considered to be one of the driving factors that are booming the growth of North American market.

3D Cell Culture market share for Asia-Pacific region is expected to rise at a CAGR of 30.7% by generating a revenue of $3,020.7 million by 2026. The market growth in the region is increasing drug discovery initiatives among pharmaceuticals and biotechnology companies in the region. Major economies such as India, Singapore, Japan and South Korea are emphasizing more on public sector openness to partnership with established companies. For instance, leading market players such as Bayer, GlaxoSmithKline and AstraZeneca are collaborating with Singapore partners across drug discovery.

View out Trending Reports with the Impact of COVID-19: https://www.researchdive.com/covid-19-insights

The major 3D Cell Culture manufacturers include QGel SA, Hrel Corporation, SynVivo, Greiner Bio-One International, Advanced BioMatrix, Lonza, Corning Incorporated, Thermo Fisher Scientific, TissUse GmbH, 3D Biotek. Players using updated technologies for their 3D Cell Culture will have good probability of having success in the rapidly blooming market. For example, Lonza has innovated the RAFT 3D Culture System that produces hepatocytes with increased stability and stronger cytochrome responses.

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:[emailprotected]LinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

Go here to see the original:
What are the 3D Cell Culture Market Key Insights and COVID-19 Business Impact? - 3rd Watch News

Read More...

Biopreservation Market share research by applications and regions for 2018 2024 – Cole of Duty

June 18th, 2020 8:48 am

Biopreservation Market will exceed USD 9.5 billion by 2024; as per a new research report.

Increasing investment in R&D activities worldwide will drive the biopreservation market growth over the forecast period. Companies and research organizations are taking efforts to develop efficient and effective product and services for biopreservation. Increasing usage of biological laboratory specimens in various research and clinical trials should further boost the biopreservation business growth.

Growing prevalence of lifestyle disorders in developed as well as developing countries will positively impact the industry growth over the coming years. Rising incidence of organ deformities coupled with shortage of organ donors for transplantation will increase the demand for regenerative medicine. Need for appropriate storage and preservation of the biological preparations will surge the demand for biopreservation equipment thereby augmenting industry growth. However, stringent regulations pertaining to manufacturing biopreservation equipment and complications associated with required temperature maintenance may hamper the business growth during the forecast period.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/762

Media segment accounted for USD 0.5 billion in 2017 and is estimated to show significant growth over forecast period. The segment growth is accredited to increasing usage of media in biopreservation process to improve post-thaw cell viability, yield and recovery. Growing demand for biopreservation media such as pre-formulated and home-brew media should further increase segment size over the coming years.

Drug discovery segment will experience 13.5% CAGR by 2024 and segmental growth will be attributable to increasing investment in R&D activities to develop efficient treatment for chronic disease. Growing adoption of stem cell models and human tissues as experimental models for preclinical drug development will foster the demand for proper preservation and storage of these biologics thereby accelerating business growth.

CD34+ segment accounted for 16.0% revenue share in 2017 due to its wide application in research and its ability to differentiate into various cell types. CD34+ cells from umbilical cord blood (UCB) can be used in treatment of chronic and non-healing wounds in patients with type 2 diabetes mellitus. Such benefits should augment the segmental revenue size during the forecast period.

Get In-depth table of contents @ https://www.gminsights.com/toc/detail/biopreservation-market

U.S. biopreservation market accounted for USD 1.6 billion in 2017 and will show similar trend during the forecast timeline. Technological developments in the U.S. coupled with rising adoption of regenerative medicine in disease treatment will surge the demand for biopreservation products. Moreover, high healthcare expenditure and advancement in healthcare facilities will further drive the business growth.

Some of the notable competitors operating in biopreservation market include: BioCision, Biomatrica, Chart MVE Biomedical, BioLife Solutions, LabVantage Solutions, Custom Biogenic Systems Atlanta Biologics, Taylor-Wharton Cryogenics, Thermo Fisher Scientific, Panasonic Biomedical, Qiagen, and VWR International. Industry players are majorly focusing on inorganic strategies such as partnership, merger, acquisition and novel product launch to strengthen their existing product portfolio and maintain market position.

See the rest here:
Biopreservation Market share research by applications and regions for 2018 2024 - Cole of Duty

Read More...

Cell Therapy Market Analysis Of Global Trends, Demand And Competition 2020-2028 – Cole of Duty

June 18th, 2020 8:48 am

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Cell Therapy Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Cell Therapy market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Cell Therapy Market

The global cell therapy market size was valued at USD 5.8 billion in 2019 and is projected to witness a CAGR of 5.4% during the forecast period. The development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. In addition, automation in adult stem cell and cord blood processing and storage are the key technological advancements that have supported the growth of the market for cell therapy.The investment in technological advancements for decentralizing manufacturing of this therapy is anticipated to significantly benefit the market. Miltenyi Biotec is one of the companies that has contributed to the decentralization in manufacturing through its CliniMACS Prodigy device. The device is an all-in-one automated manufacturing system that exhibits the capability of manufacturing various cell types.

An increase in financing and investments in the space to support the launch of new companies is expected to boost the organic revenue growth in the market for cell therapy. For instance, in July 2019, Bayer invested USD 215 million for the launch of Century Therapeutics, a U.S.-based biotechnology startup that aimed at developing therapies for solid tumors and blood cancer. Funding was further increased to USD 250 billion by a USD 35 million contribution from Versant Ventures and Fujifilm Cellular Dynamics.The biomanufacturing companies are working in collaboration with customers and other stakeholders to enhance the clinical development and commercial manufacturing of these therapies. Biomanufacturers and OEMs such as GE healthcare are providing end-to-end flexible technology solutions to accelerate the rapid launch of therapies in the market for cell therapy.The expanding stem cells arena has also triggered the entry of new players in the market for cell therapy. Celularity, Century Therapeutics, Rubius Therapeutics, ViaCyte, Fate Therapeutics, ReNeuron, Magenta Therapeutics, Frequency Therapeutics, Promethera Biosciences, and Cellular Dynamics are some startups that have begun their business in this arena lately.Use-type InsightsThe clinical-use segment is expected to grow lucratively during the forecast period owing to the expanding pipeline for therapies. The number of cancer cellular therapies in the pipeline rose from 753 in 2018 to 1,011 in 2019, as per Cancer Research Institute (CRI). The major application of stem cell treatment is hematopoietic stem cell transplantation for the treatment of the immune system and blood disorders for cancer patients.In Europe, blood stem cells are used for the treatment of more than 26,000 patients each year. These factors have driven the revenue for malignancies and autoimmune disorders segment. Currently, most of the stem cells used are derived from bone marrow, blood, and umbilical cord resulting in the larger revenue share in this segment.On the other hand, cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized to possess high growth potential. As a result, a several research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.TherapyType Insights of Cell Therapy Market

An inclination of physicians towards therapeutic use of autologous and allogeneic cord blood coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation. Currently, the allogeneic therapies segment accounted for the largest share in 2019 in the cell therapy market. The presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

Furthermore, the practice of autologous tissue transplantation is restricted by the limited availability of healthy tissue in the patient. Moreover, this type of tissue transplantation is not recommended for young patients wherein tissues are in the growth and development phase. Allogeneic tissue transplantation has effectively addressed the above-mentioned challenges associated with the use of autologous transplantation.However, autologous therapies are growing at the fastest growth rate owing to various advantages over allogeneic therapies, which are expected to boost adoption in this segment. Various advantages include easy availability, no need for HLA-matched donor identification, lower risk of life-threatening complications, a rare occurrence of graft failure, and low mortality rate.

Regional Insights of Cell Therapy Market

The presence of leading universities such as the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, and Yale Stem Cell Center that support research activities in U.S. is one of the key factor driving the market for cell therapy in North America. Moreover, strong regulatory and financing support from the federal bodies for expansion of this arena in U.S. as well as Canada is driving the market.In Asia Pacific, the market is anticipated to emerge as a lucrative source of revenue owing to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management. Japan is leading the Asian market for cell therapy, which can be attributed to its fast growth as a hub for research on regenerative medicine.Moreover, the Japan government has recognized regenerative medicine and cell therapy as a key contributor to the countrys economic growth. This has positively influenced the attention of global players towards the Asian market, thereby driving marketing operations in the region.

Market Share Insights of Cell Therapy Market

Some key companies operating in this market for cell therapy are Fibrocell Science, Inc.; JCR Pharmaceuticals Co. Ltd.; Kolon TissueGene, Inc.; PHARMICELL Co., Ltd.; Osiris Therapeutics, Inc.; MEDIPOST; Cells for Cells; NuVasive, Inc.; Stemedica Cell Technologies, Inc.; Vericel Corporation; and ANTEROGEN.CO.,LTD. These companies are collaborating with the blood centers and plasma collection centers in order to obtain cells for use in therapeutics development.Several companies have marked their presence in the market by acquiring small and emerging therapy developers. For instance, in August 2019, Bayer acquired BlueRock Therapeutics to establish its position in the market for cell therapy. BlueRock Therapeutics is a U.S. company that relies on a proprietary induced pluripotent stem cell (iPSC) platform for cell therapy development.Several companies are making an entry in the space through the Contract Development and Manufacturing Organization (CDMO) business model. For example, in April 2019, Hitachi Chemical Co. Ltd. acquired apceth Biopharma GmbH to expand its global footprint in the CDMO market for cell and gene therapy manufacturing.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Cell Therapy Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2030. For the purpose of this study, this market research report has segmented the global cell therapy market on the basis of use-type, therapy-type, and region:

Use-Type Outlook (Revenue, USD Million, 2019 2030)

Clinical-use

By Therapeutic Area

Malignancies

Musculoskeletal Disorders

Autoimmune Disorders

Dermatology

Others

By Cell Type

Stem Cell Therapies

BM, Blood, & Umbilical Cord-derived Stem Cells

Adipose derived cells

Others

Non-stem Cell Therapies

Research-use

Therapy Type Outlook (Revenue, USD Million, 2019 2030)

Allogeneic Therapies

Autologous Therapies

Quick Read Table of Contents of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See the article here:
Cell Therapy Market Analysis Of Global Trends, Demand And Competition 2020-2028 - Cole of Duty

Read More...

Page 492«..1020..491492493494..500510..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick